Jason Poston's peptide content: separating real science from gym lore

What did @jasonposton_ actually say?

Jason's core argument is that tesamorelin used alone is a suboptimal purchase because it relies on the body's natural ghrelin and GHRH signaling and gets "limited" by somatostatin. He says tesamorelin's growth hormone pulse lasts roughly 26 minutes, while ipamorelin sustains a pulse for "six to eight hours." His recommendation: buy a blend of both, because ipamorelin "actively suppresses somatostatin" and extends the release window for better fat loss, muscle retention, recovery, and sleep.

He's not saying tesamorelin is useless. He's saying tesamorelin alone is leaving results on the table, and that the combination is meaningfully superior. That framing matters when we look at what the evidence actually says.

Does the science back this up?

Partially. The mechanistic logic is sound, but the clinical evidence for the combo outperforming tesamorelin alone is thinner than Jason implies. Tesamorelin's efficacy as a standalone compound is well-documented in FDA-approved research for visceral fat reduction in HIV-associated lipodystrophy (Falutz et al., 2010, New England Journal of Medicine). That approval was based on tesamorelin alone, not a blend.

The somatostatin suppression argument for ipamorelin is mechanistically accurate. Ipamorelin is a selective ghrelin receptor agonist and GHRP that does reduce somatostatin tone, which in turn extends GH pulse duration (Raun et al., 1998, European Journal of Endocrinology). The combination of a GHRH analog with a GHRP to produce synergistic GH release is a real pharmacological principle documented in research (Jaffe et al., 1993, Journal of Clinical Endocrinology and Metabolism). The problem is that most of this synergy research used older GHRPs like GHRP-2 or GHRP-6, not ipamorelin specifically, and was conducted in controlled clinical settings, not healthy adults seeking body composition optimization.

What did they get wrong (or right)?

Jason gets the mechanistic framework mostly right. GHRH peptides like tesamorelin do depend on low somatostatin tone to work effectively. Combining a GHRH analog with a GHRP does produce additive or synergistic GH secretion in research settings. He deserves credit for explaining why the combination is theoretically superior rather than just asserting it.

Where he oversimplifies: his "26 minutes versus six to eight hours" pulse duration framing is a loose approximation, not a finding from a comparative clinical trial. The half-life of tesamorelin is roughly 26-38 minutes (Falutz et al., 2007, Journal of Clinical Endocrinology and Metabolism), but GH pulse duration and peptide half-life are not interchangeable numbers. Ipamorelin's GH-stimulating effect lasting "six to eight hours" is not supported by a specific citation and appears to conflate duration of elevated IGF-1 with acute GH pulse behavior.

He also frames tesamorelin alone as money wasted when it has the strongest human clinical data of any peptide in the category. That's a significant overstatement.

What should you actually know?

The GHRH plus GHRP combination principle is real science, not bro-science. But the specific numbers Jason cites, the product recommendations, and the implied equivalence between research-grade pharmacology and compounded telehealth blends deserve scrutiny.

• Tesamorelin is the only peptide in this category with FDA approval, based on multicenter randomized controlled trials. Using it alone is not "wasting money" by any evidence-based standard.
• Ipamorelin has a cleaner selectivity profile than older GHRPs like GHRP-6, meaning fewer cortisol and prolactin side effects (Raun et al., 1998). That selectivity is a legitimate reason to prefer it in a combination protocol.
• The synergistic GH response from combining GHRH analogs with GHRPs has been documented, but most human data comes from GH-deficient populations or older adults, not healthy individuals seeking optimization.
• Compounded peptide blends vary in purity, concentration, and sterility. Quality is not uniform across compounding pharmacies, and no blended tesamorelin-ipamorelin product carries FDA approval.
• Anyone considering these compounds should be working with a licensed provider who can monitor IGF-1 levels and assess individual risk factors, not following a TikTok protocol.

The bottom line

Jason's mechanistic reasoning is more grounded than most peptide content on the platform. The somatostatin suppression argument is real, and the combination rationale is defensible. But calling solo tesamorelin a waste when it has robust FDA-approved clinical data is a stretch. The "26 minutes versus six to eight hours" framing needs a source, not just a confident delivery. And none of this applies uniformly to healthy people optimizing body composition, because that population is largely absent from the clinical literature supporting these compounds.